Last reviewed · How we verify
daily TDF/FTC
TDF/FTC is a fixed-dose combination of two nucleoside reverse transcriptase inhibitors that block HIV reverse transcriptase to prevent viral replication.
TDF/FTC is a fixed-dose combination of two nucleoside reverse transcriptase inhibitors that block HIV reverse transcriptase to prevent viral replication. Used for HIV-1 prevention (pre-exposure prophylaxis, PrEP), HIV-1 treatment as part of antiretroviral therapy.
At a glance
| Generic name | daily TDF/FTC |
|---|---|
| Also known as | truvada |
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Drug class | Nucleoside/nucleotide reverse transcriptase inhibitor combination |
| Target | HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | Phase 3 |
Mechanism of action
Tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) are nucleoside/nucleotide reverse transcriptase inhibitors that work synergistically to inhibit HIV reverse transcriptase, preventing the conversion of viral RNA to DNA and blocking HIV replication. This combination is used both as antiretroviral therapy for HIV-infected individuals and as pre-exposure prophylaxis (PrEP) to prevent HIV acquisition in high-risk populations.
Approved indications
- HIV-1 prevention (pre-exposure prophylaxis, PrEP)
- HIV-1 treatment as part of antiretroviral therapy
Common side effects
- Renal dysfunction / decreased glomerular filtration rate
- Bone mineral density loss
- Nausea
- Diarrhea
- Headache
- Abdominal pain
Key clinical trials
- A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062) (PHASE2, PHASE3)
- Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018) (PHASE3)
- ImPrEP LEN Brasil: Twice-Yearly Lenacapavir for HIV Prevention (NA)
- Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in Adolescents and Children With Human Immunodeficiency Virus-1 (PHASE2, PHASE3)
- A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010) (PHASE3)
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011) (PHASE3)
- Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- daily TDF/FTC CI brief — competitive landscape report
- daily TDF/FTC updates RSS · CI watch RSS
- National Institute of Allergy and Infectious Diseases (NIAID) portfolio CI